
Meridian Bioscience VIVO
Quartalsbericht 2022-Q4
hinzugefügt 09.02.2023
Meridian Bioscience Betriebsaufwand 2011-2026 | VIVO
Betriebsaufwand Jährlich Meridian Bioscience
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 134 M | 108 M | 94.9 M | 81 M | 85.8 M | 80.8 M | 74.3 M | 65.8 M | 64.9 M | 63.7 M | 60.6 M | 59.3 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 134 M | 59.3 M | 81.1 M |
Betriebsaufwand Vierteljährlich Meridian Bioscience
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59.6 M | - | - | 32.3 M | 28.9 M | - | 21.4 M | 23.6 M | 26.9 M | 66.3 M | 21.3 M | 26.9 M | 22.3 M | 62.3 M | 21.8 M | 22 M | 21 M | 74.1 M | 23.2 M | 21 M | 23.9 M | 65.1 M | 26.8 M | 23.7 M | 19 M | 55.6 M | 19.2 M | 19.4 M | 18 M | 49.3 M | 15.9 M | 18 M | 16.6 M | 48.4 M | 16.1 M | 16.6 M | 16.4 M | 46.1 M | 14.9 M | 16.4 M | 15.7 M | 44.3 M | 14.8 M | 15.7 M | 14.7 M | 44.6 M | 15.2 M | 14.9 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 74.1 M | 14.7 M | 28.9 M |
Betriebsaufwand anderer Aktien in der Diagnostik & Forschung
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M | ||
|
Bioventus
BVS
|
217 M | $ 9.26 | 1.09 % | $ 617 M | ||
|
Biodesix
BDSX
|
106 M | $ 14.6 | -3.63 % | $ 1.89 B | ||
|
DarioHealth Corp.
DRIO
|
49.3 M | $ 8.45 | 9.74 % | $ 33.7 M | ||
|
DexCom
DXCM
|
1.89 B | $ 66.09 | -1.12 % | $ 25.8 B | ||
|
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
2.47 B | - | - | $ 19.8 B | ||
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M | ||
|
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M | ||
|
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M | ||
|
ICON Public Limited Company
ICLR
|
408 M | $ 103.08 | 3.09 % | $ 8.5 B | ||
|
IDEXX Laboratories
IDXX
|
1.3 B | $ 573.29 | -0.42 % | $ 46.1 B | ||
|
Illumina
ILMN
|
3.69 B | $ 124.4 | -1.43 % | $ 19.8 B | ||
|
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | ||
|
Aspira Women's Health
AWH
|
37.1 M | - | -6.19 % | $ 10.5 M | ||
|
Co-Diagnostics
CODX
|
45.3 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | ||
|
Medpace Holdings
MEDP
|
118 M | $ 466.6 | -0.04 % | $ 13.5 B | ||
|
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | ||
|
Myriad Genetics
MYGN
|
964 M | $ 4.62 | -1.28 % | $ 428 M | ||
|
National Research Corporation
NRC
|
38.5 M | $ 17.52 | 1.98 % | $ 392 M | ||
|
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | ||
|
Natera
NTRA
|
258 M | $ 196.15 | -0.62 % | $ 19.3 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | ||
|
Charles River Laboratories International
CRL
|
607 M | $ 165.13 | -0.46 % | $ 8.18 B | ||
|
Organovo Holdings
ONVO
|
23.3 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
21.9 M | - | -16.95 % | $ 1.54 M | ||
|
OPKO Health
OPK
|
217 M | $ 1.17 | -1.68 % | $ 812 M | ||
|
Pacific Biosciences of California
PACB
|
600 M | $ 1.35 | -2.88 % | $ 405 M | ||
|
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | ||
|
ENDRA Life Sciences
NDRA
|
10.8 M | $ 4.59 | 22.4 % | $ 2.46 M | ||
|
PerkinElmer
PKI
|
1.07 B | - | -0.91 % | $ 14.7 B | ||
|
Invitae Corporation
NVTA
|
343 M | - | - | $ 21.2 M | ||
|
Personalis
PSNL
|
44.5 M | $ 7.32 | -4.94 % | $ 434 M | ||
|
Interpace Biosciences
IDXG
|
21.8 M | $ 1.73 | 2.37 % | $ 7.59 M | ||
|
RadNet
RDNT
|
1.98 B | $ 59.41 | -2.06 % | $ 4.47 B | ||
|
Motus GI Holdings
MOTS
|
18.6 M | - | -34.28 % | $ 263 K | ||
|
QIAGEN N.V.
QGEN
|
821 M | - | - | $ 10.6 B | ||
|
Celcuity
CELC
|
172 M | $ 114.81 | 4.16 % | $ 4.53 B | ||
|
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | ||
|
Senseonics Holdings
SENS
|
61.8 M | $ 6.56 | -2.96 % | $ 274 M | ||
|
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 268.38 | 0.89 % | $ 22.3 B | ||
|
NeoGenomics
NEO
|
430 M | $ 7.76 | -0.13 % | $ 994 M | ||
|
Soleno Therapeutics
SLNO
|
181 M | $ 31.83 | -0.03 % | $ 1.62 B | ||
|
Psychemedics Corporation
PMD
|
11.3 M | - | -1.84 % | $ 15.3 M | ||
|
Precipio
PRPO
|
13.6 M | $ 27.2 | -0.15 % | $ 35.3 M |